A randomized, open-label study of the effect of CellCept , Zenepax (daclizumab), and corticosteroids, with delayed introduction of sirolimus plus discontinuation of ciclosporin, on renal function in kidney transplant patients

Trial Profile

A randomized, open-label study of the effect of CellCept , Zenepax (daclizumab), and corticosteroids, with delayed introduction of sirolimus plus discontinuation of ciclosporin, on renal function in kidney transplant patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2011

At a glance

  • Drugs Ciclosporin; Mycophenolate mofetil; Sirolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CONCEPT
  • Sponsors Roche
  • Most Recent Events

    • 19 Sep 2011 Pharmacodynamic substudy results published in the American Journal of Transplantation.
    • 07 Sep 2011 Five-year renal function data presented at the 15th Congress of the European Society for Organ Transplantation.
    • 26 May 2011 Vascular endothelial growth factor substudy results published in Nephrology Dialysis Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top